Fairvalue-Calculator Fairvalue-Calculator
EN DE

Genesystem Co (363250) Fair Value & Analysis

Healthcare · KR · Market cap 25.6B KRW

Price3,625 KRW
Fair Value2,072 KRW
Upside-42.8%
Quality94/100
Evidence: Low Range 1,554 KRW – 2,590 KRW

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Genesystem Co (363250) currently trades at 3,625 KRW, while our model-based Fair Value estimate is 2,072 KRW — implying the stock looks roughly 42.8% overvalued today. We read business quality at 94/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Genesystem Co., Ltd., a biotech engineering company, specializes in molecular testing solutions to target on-site testing needs. The company offers PCR systems, multiplex biochips, and PCR reagents. It also provides human pathogen assays, including novel coronavirus (SARS-CoV-2) detection kits, SARS-CoV-2/Flu/RSV simultaneous detection kits, and mycobacterium tuberculosis detection kits; veterinary diagnostics; food safety assays comprising foodborne pathogen detection kits, HALAL food testing kits, and meat species identification kits; and nucleic acid extraction assays, such as extraction kits, extraction buffers, lysis buffers, and gDNA extraction kits. The company was incorporated in 2010 and is based in Daejeon, South Korea.

Open the full interactive analysis →

Similar stocks

Frequently asked questions

Is Genesystem Co (363250) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 2,072 KRW versus a price of 3,625 KRW — about −43% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 363250?
Our 21-model fair value for Genesystem Co is 2,072 KRW (as of Jun 24, 2026), built from audited fundamentals. The current price is 3,625 KRW.
What is the quality score of 363250?
Genesystem Co has a Quality Score of 94/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.